Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Global Prevalence of Occult Hepatitis B Global Prevalence of Occult Hepatitis B
A better understanding of the prevalence of occult HBV infection in the global population could lead to the development of better prevention and management strategies.Journal of Viral Hepatitis (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 30, 2022 Category: Intensive Care Tags: Gastroenterology Journal Article Source Type: news
Peninsula biotech breaks off hepatitis B deal after partner's drug falters
It is the fourth strike this year against Bay Area drug developers trying to find a potential cure for hepatitis B. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 25, 2022 Category: American Health Authors: Ron Leuty Source Type: news
Africa: WHO DG Recounts Successes in War Against HIV, Malaria, Other Diseases #WHA75
[Premium Times] He noted that 15 countries have been validated for eliminating mother-to-child transmission of HIV and/or syphilis, adding that the SDG target on hepatitis B has been met. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 23, 2022 Category: African Health Source Type: news
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Media News - May 12, 2022 Category: Pharmaceuticals Source Type: news
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Investor Update - May 12, 2022 Category: Pharmaceuticals Source Type: news
Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
NEW BRUNSWICK, NJ, May 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.No clinical studies in hepatitis B have been initiated by Janssen ut...
Source: Johnson and Johnson - May 9, 2022 Category: Pharmaceuticals Source Type: news
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes detecting four infections simultaneously
Test provides a critically important tool as people return to regular... Diagnostics, FDA Abbott, Alinity m, Hepatitis C, Hepatitis B, HIV (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2022 Category: Pharmaceuticals Source Type: news
Why I Recommend Hepatitis B Vaccination to All My Patients Why I Recommend Hepatitis B Vaccination to All My Patients
New age-based hepatitis B vaccine recommendations and available vaccine products are reviewed by Dr Sandra Fryhofer.Medscape Internal Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 3, 2022 Category: Infectious Diseases Tags: Internal Medicine Commentary Source Type: news
Lupin gets USFDA nod to market drug used to treat chronic hepatitis B
The company has received tentative approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg), Lupin said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 18, 2022 Category: Pharmaceuticals Source Type: news
Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety
Do tenofovir and entecavir differ in their long-term impact on renal function in patients with hepatitis B?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
CDC Recommends Hep B Vaccination for Most Adults CDC Recommends Hep B Vaccination for Most Adults
Faced with an increasing incidence of hepatitis B infection, the Centers for Disease Control and Prevention expanded its vaccination recommendation to include most adults.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 2, 2022 Category: Infectious Diseases Tags: Gastroenterology News Source Type: news
Risk for Acute MI Not Increased With Two-Dose HepB-CpG Vaccine
FRIDAY, April 1, 2022 -- The rate of type 1 acute myocardial infarction (MI) is not increased with receipt of the two-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) versus the three-dose hepatitis B vaccine with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2022 Category: Pharmaceuticals Source Type: news
Universal HepB Vaccination Recommended for Adults Age 19 to 59
THURSDAY, March 31, 2022 -- Hepatitis B (HepB) vaccination should be administered to adults aged 19 to 59 years and to those aged 60 years or older with risk factors for HepB, according to updated recommendations published in the April 1 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2022 Category: Pharmaceuticals Source Type: news
